Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
But now it must show that varseta-M can move into a registrational trial.
New data with pasritamig plus docetaxel support a recent pivotal start.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
